Thymalin 10 mg*10vials Kit

Description

🧪 Product Profile: Thymalin

Product Name: Thymalin
CAS Number: 79621-14-0
Category: Bioactive peptide complex (thymic extract-derived)
Form: Lyophilized sterile powder for injection
Purity: ≥99% (HPLC verified)
Molecular Composition: Mixture of low-molecular-weight peptides (<10 kDa) isolated from animal thymus tissue

🔍 Key Properties

• Physical Characteristics: White to off-white amorphous powder; soluble in sterile water (10 mg/mL)
• Storage Stability:
  • Lyophilized form: 2-8°C for 24 months (protected from light and moisture)
  • Reconstituted solution: Use immediately or refrigerate (2-8°C) for ≤24 hours
• Supply Specifications: Available in 1g/vial, 5g/vial, or custom packaging; minimum order: 1 box

🛡️ Mechanism of Action

Thymalin functions as an immunomodulatory peptide through multiple pathways:

• T-Cell Differentiation: Promotes maturation of thymocytes into functional T-lymphocytes (CD4+ and CD8+ subsets)
• Immune Response Enhancement: Upregulates cytokine production (IL-2, IFN-γ) and natural killer (NK) cell activity
• Cellular Repair Support: Stimulates DNA synthesis in lymphocytes and accelerates tissue regeneration in immunocompromised states
• Immune Homeostasis: Balances overactive or suppressed immune systems by regulating macrophage phagocytosis and antibody production

🧠 Research Applications

Primarily investigated in preclinical and clinical research for:

• Immunodeficiency Disorders: Treatment models for congenital or acquired immune deficiencies (e.g., HIV-associated lymphopenia)
• Autoimmune Diseases: Adjunct therapy in rheumatoid arthritis and multiple sclerosis (via immune tolerance induction)
• Neuropsychiatric Research: As a co-adjuvant in therapy-resistant schizophrenia, where immune abnormalities correlate with symptom severity (Russian clinical studies, 1990s)
• Oncology Support: Potential to mitigate chemotherapy-induced myelosuppression (preclinical models)

⚙️ Handling & Administration

• Reconstitution: Dissolve lyophilized powder in 1-2 mL sterile saline or water for injection
• Route: Intramuscular or subcutaneous injection (research settings); intravenous administration under clinical supervision
• Dosing: Typically 5-10 mg/day for 10-14 days in rodent models; human equivalent doses require further validation

⚠️ Safety Considerations

• Research Use Only (RUO): Not approved for human clinical use in most regions
• Contraindications: Hypersensitivity to thymic extracts; acute infections (may exacerbate inflammation)
• Adverse Effects: Mild injection site pain; rare: transient fever or lymphadenopathy